Back

Comparing clinical outcomes following 1 year of dual antiplatelet therapy in patients risk stratified by the PRECISE-DAPT and DAPT scores

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Antithrombotic Therapy Update Antiplatelet Drugs ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Rene Boudreau

University of Ottawa Heart Institute, Ottawa (Canada)

6 More presentations in this session

Presentation thumbnail
First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-986177/JNJ-70033093, a direct, reversible, small molecule Factor XIa inhibitor in healthy volunteers
Doctor V. Perera (Berlin, DE)
Abstract Slides
Presentation thumbnail
S62798, a TAFIa inhibitor, accelerates endogenous thrombolysis in a murine model of pulmonary thromboembolism
Doctor P. Sansilvestri-Morel (Suresnes, FR)
Abstract Slides
Presentation thumbnail
Favorable therapeutic index of an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, compared with the P2Y12 antagonist ticagrelor in cynomolgus monkeys
Doctor P. Wong (Princeton, US)
Abstract Slides
Presentation thumbnail
Orodispersible ticagrelor use in acute coronary syndrome patients: the Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation (TASTER) Study
Professor G. Parodi (Sassari, IT)
Abstract Slides
Presentation thumbnail
Adherence to dual anti-platelet therapy after acute coronary syndrome and its impact on patient outcome
Doctor P. Sulzgruber (Krems an der Donau, AT)
Abstract Slides

Access the full session

Session thumbnail
Antithrombotic Therapy Update

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Parenteral antiplatelet agents: when should they be used?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources